BSI-082

BSI-082 is a best-in-class, highly differentiated, fully human anti-SIRPα antagonistic monoclonal antibody. It exhibits robust binding affinity across the huSIRPα protein variants V1, V2, and V8, thereby achieving a population coverage of over 90%. BSI-082 specifically binds to SIRPα and SIRPβ without cross-reacting with SIRPγ. This specificity allows it to effectively block the interaction between SIRPα and CD47, which transmits the "don't eat me" signal to macrophages, thereby restoring the phagocytic capacity of macrophages and dendritic cells against tumor cells. Simultaneously, this approach successfully bypasses the severe toxicity and side-effect challenges commonly encountered in CD47-targeted therapies. In multiple animal models, BSI-082 has demonstrated potent in vivo antitumor efficacy when used in combination with monoclonal antibodies targeting tumor-associated antigens (TAAs).